SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending due to initial alarm from a Stocktwits pricing glitch and concerns over geopolitical events impacting South Korean memory chip rivals, though many in the community argue these events could actually benefit $MU given its limited exposure and strong demand for its AI-driven HBM products ahead of strong earnings expectations.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending amid geopolitical volatility in the Middle East, which initially triggered declines but quickly shifted to a pronounced intraday "V-shaped" recovery. Community discussions highlight this pattern, with market sentiment turning positive on reports of US assurances to secure shipping lanes through the Strait of Hormuz and claims of successful military actions against Iranian assets.

SSgA Active Trust - State Street SPDR Dow Jones Industrial Average ETF Trust

The SPDR Dow Jones Industrial Average ETF is trending as breaking reports of Iran's Supreme Leader being killed and subsequent negotiation offers ignite intense market volatility. The community is sharply divided between anticipating a short squeeze or a broader downturn, with ongoing concerns about oil prices and geopolitical instability driving widespread debate.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

TQQQ is highly volatile amid escalating Middle East tensions, fueling fears of rising oil prices and inflation, alongside market uncertainty over new tariffs and AI's impact on tech. The community is sharply divided between those bracing for further declines and aggressive dip-buyers anticipating a significant rally or short squeeze in the leveraged tech ETF.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JD.com is generating significant debate ahead of its imminent earnings report, as frustrated investors grapple with its continued decline to new 52-week lows, while others point to deep undervaluation and strong fundamentals amidst intense sector competition and geopolitical concerns.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is experiencing a surge in attention due to escalating geopolitical tensions highlighting the critical role of drone technology in modern warfare. Community discussion is buzzing with expectations of a short squeeze and imminent results from the Drone Dominance Gauntlet program, which could further solidify the company's position in defense solutions.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

DJIA is trending amidst heightened geopolitical tensions, including ongoing developments in the Middle East and tariff discussions, which are driving broad market volatility. Community sentiment is sharply divided, with some expressing optimism for market resilience and potential gains, while others voice concerns about a broader economic downturn and market vulnerability.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is a hot topic following an earnings call that showcased robust ANKTIVA revenue growth and plans for immediate global product shipments, sparking community debate between long-term optimism for a cancer cure and short-term investor disappointment over financial guidance amidst active short-seller sentiment.

BlackRock Institutional Trust Company N.A. - iShares MSCI South Korea ETF

iShares MSCI South Korea ETF

EWY is trending as South Korea's market experienced a significant decline, triggering circuit breakers amid surging oil and LNG prices fueled by geopolitical tensions, which led to a massive sell-off in key semiconductor holdings like Samsung and SK Hynix; the community is actively debating whether this represents an excessive correction and a prime buying opportunity or a sign of an over-extended market.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network Inc. is trending amidst high anticipation of a short squeeze, fueled by an exceptionally high cost to borrow and limited share availability. The AI stock is drawing significant community attention, with traders eyeing multi-fold price appreciation and noting its strong performance against broader market conditions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aurinia Pharmaceuticals (NASDAQ:AUPH) Director Buys $7,224,981.61 in Stock

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) (TSE:AUP) Director Kevin Tang purchased 516,439 shares of Aurinia Pharmaceuticals stock in a transaction dated Friday, February 27th. The...

GSA Capital Partners LLP Trims Stake in Aurinia Pharmaceuticals Inc $AUPH

GSA Capital Partners LLP trimmed its position in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) (TSE:AUP) by 95.9% in the 3rd quarter, according to its most recent 13F filing with the...

Aurinia Pharmaceuticals (NASDAQ:AUPH) Posts Earnings Results

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) (TSE:AUP) issued its quarterly earnings results on Thursday. The biotechnology company reported $1.53 earnings per share (EPS) for the quarter...

Aurinia Pharmaceuticals Q4 Earnings Call Highlights

Aurinia Pharmaceuticals (NASDAQ:AUPH) reported fourth-quarter and full-year 2025 results on its latest earnings call, highlighting continued growth from its lupus nephritis therapy LUPKYNIS and...

Aurinia Pharmaceuticals (AUPH) Tops Q4 Earnings and Revenue Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of +25.79% and +3.64%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

<ul class="summary-bullets"><li>Aurinia stated that the revenue from the sales of LUPKYNIS for the treatment of active lupus nephritis rose 29% YoY in Q4 to $74.2 million and 25% YoY for the full year to $271 million.</li><li>LUPKYNIS is the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, the company said.</li><li>Overall, LUPKYNIS sales accounted for about 96% of the company’s total revenue in Q4 and for the full year 2025.</li></ul>Aurinia Pharmaceuticals Inc. (AUPH) shares gained nearly 4% in Thursday’s pre-market trade after the company posted a fourth-quarter (Q4) earnings and revenue beat.Aurinia reported adjusted earnings per share (EPS) of $1.53 on revenue of $77.1 million, while Wall Street analysts expected an adjusted EPS of $0.22 on revenue of $74.7 million, according to Koyfin data.However, the company’s 2026 revenue guidance fell short of Wall Street expectations. Aurinia guided for revenue in the range of $315 million and $325 million during the year, but the consensus estimate stood at $326.8 million.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/AUPH">Aurinia Pharmaceuticals</a> trended in the ‘bullish’ territory, with message volumes at ‘high’ levels. The stock was among the top three trending tickers on the platform at the time of writing.<h2 class="st-heading-2">Active Lupus Nephritis Therapy Sales Gain Momentum</h2>Aurinia stated that the revenue from the sales of LUPKYNIS for the treatment of active lupus nephritis rose 29% YoY in Q4 to $74.2 million. For the full year, LUPKYNIS sales stood at $271 million, rising 25% YoY.LUPKYNIS is the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, the company said.Overall, LUPKYNIS sales contributed to about 96% of the company’s total revenue in Q4 as well as the full year 2025.Aurinia also stated that the full-year revenue includes a $10 million milestone payment received by the company following the approval of LUPKYNIS by regulators in Japan.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>One user called Aurinia’s earnings and cash position “solid.”<stembedurl>https://stocktwits.com/VSTN/message/645950955</stembedurl>Another user called Aurinia’s numbers “excellent,” saying they’re excited for the company's long-term shareholders.<stembedurl>https://stocktwits.com/Ballerdad1/message/645950749</stembedurl><a href="https://stocktwits.com/symbol/AUPH">AUPH stock</a> is down 10% year-to-date, but up 80% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/celh-stock-soaring-today-celsius-q4-earnings-beat/cZTG9gDRIb8">CELH Stock Is Soaring Pre-Market Today — What Is Driving The Surge?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Aurinia Pharmaceuticals logo is seen displayed on a smartphone screen

AUPH Stock Gains On Aurinia Pharma’s Q4 Beat, But 2026 Guidance Misses Estimates

Aurinia reported adjusted earnings per share of $1.53 on revenue of $77.1 million, while Wall Street analysts expected an adjusted EPS of $0.22 on revenue of $74.7 million, according to Koyfin data.

Equity

Earnings Summary: Aurinia Pharmaceuticals Q4

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and twelve months ended December 31, 2025 and provided an update on recent business progress. Financial...

Earnings Preview: Aurinia Pharmaceuticals

United Therapeutics (UTHR) Surpasses Q4 Earnings Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of +13.50% and -1.88%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Software / SaaS

Cybersecurity

Cloud Infrastructure

AI / Semiconductors

Which beaten-down sector are you buying first?

Stocktwits

Stocktwits Polls

Investor Tang has significantly increased his stake to ~18% voting power, sparking speculation about a major catalyst or management changes.

Shareholders are vocalizing strong discontent with the CEO, pushing for accountability and potential changes in leadership amid performance and transparency concerns.

High off-exchange short volume and recent spikes in trading activity are fueling predictions of an impending short squeeze and price rally.

Traders are keenly awaiting an update on the AUR200 clinical trial, believing clarity on its status is crucial for future share price momentum.

AUPH
Aurinia Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AUPH News

AUPHAurinia Pharmaceuticals Inc